Hanmi Pharmaceutical was named an innovation leader in an assessment of research and development (R&D) productivity of pharmaceutical and biotech corporations in Asia and emerging markets, released by the international journal Nature Reviews Drug Discovery.
Hanmi Pharmaceutical said on the 6th that in the paper "Trends in R&D productivity of biopharma corporations in Asia and emerging markets," published in Nature Reviews Drug Discovery, an international journal on drug development issued by Nature, it was classified as an innovation leader based on an analysis of 45 major pharmaceutical and biotech corporations in Asia, Latin America, and Eastern Europe–Middle East–Africa (EEMEA).
The study evaluated research and development productivity and innovation capabilities by comprehensively analyzing R&D investment ratio, clinical pipelines, and sales for pharmaceutical and biotech corporations with annual revenue of $500 million (about 760 billion won) or more over the past 15 years from 2010 to 2025.
The researchers classified corporations into three groups: ◇ innovation leaders ◇ emerging innovators ◇ generic corporations.
Hanmi Pharmaceutical was included among the innovation leaders in recognition of its R&D strategy and productivity centered on innovative new drugs. In particular, although its R&D investment ratio to sales in this group was about 17%, one of the lowest levels, the company said it showed high R&D productivity based on a pipeline focused on innovative new drugs and performance in global technology out-licensing.
The paper presented Hanmi Pharmaceutical as a case of transitioning into an innovation-focused corporation by fostering metabolic diseases and rare diseases as core research areas. The authors said, "Innovation-leading pharmaceutical and biotech corporations in Asia, especially Korea and China, are poised to grow into strong competitors to corporations in the United States and Europe based on their innovation strategies."
Hanmi Pharmaceutical invests a double-digit percentage of its sales in research and development every year and is pursuing new drug development in obesity and metabolic diseases, oncology, and rare diseases.
Choi In-young, head of future growth at Hanmi Pharmaceutical (executive vice president), said, "This assessment is meaningful in that, beyond the scale of R&D investment, our R&D strategy and performance centered on innovative new drugs were recognized in terms of R&D productivity," adding, "We will continue differentiated innovative new drug development and strengthen global R&D competitiveness."